Bendamustine: A new treatment option for chronic lymphocytic leukemia

Pharmacotherapy

Volumn 29, Issue 11, 2009, Pages 1375-1384

  Glode, Ashley E ^a   Jarkowski III, Anthony ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Bendamustine; Chronic lymphocytic leukemia; CLL; SCX 105; SyB L 0501; Treanda

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; FLAVOPIRIDOL; FLUDARABINE; GEMCITABINE; METHYLPREDNISOLONE; PACLITAXEL; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANEMIA; CHEMICAL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; FIRST PASS EFFECT; HUMAN; HYPERURICEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MOLECULAR STRUCTURE; NITROGEN MUSTARD COMPOUNDS; TREATMENT OUTCOME;

EID: 70350493184     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.11.1375     Document Type: Review

References (64)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-Hodgkin's lymphomas. Available from www.nccn.org. Accessed March 29, 2009.
2. Schwanen C, Hecker T, Hubinger G, et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002;16:2096-2105
3. National Cancer Institute. Surveillance epidemiology and end results stat fact sheets. Cancer: chronic lymphocytic leukemia. Available from seer.cancer.gov/statfacts/html/clyl.html. Accessed December 1, 2008.
4. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757
5. Raphael B, Andersen J, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an eastern cooperative oncology group randomized clinical trial. J Clin Oncol 1991;9(5):770-776
6. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-3281 (Pubitemid 38525651)
7. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088 (Pubitemid 46211313)
8. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25(35):5616-5623
9. Knauf WU, Lissichov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study [abstract]. Blood 2007;110:abstract 2043.
10. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712). Blood 2003;101:6-14.
11. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-4078 (Pubitemid 46211312)
12. Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III reach trial [abstract]. Blood 2008;112(11):abstract LBA-1.
13. Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract]. Blood 2008;112(11):abstract 325.
14. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112(4):975-980
15. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575-1581 (Pubitemid 46638781)
16. Kay NE, Geyer SM, Call TG, et al. Combination chemotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-411
17. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 2007;25:793-798 (Pubitemid 350002879)
18. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomized controlled trial. Lancet 2007;370:230-239 (Pubitemid 47069536)
19. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolonerituximab is effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007; 48(12):2412-2417
20. Hainsworth JD, Burris HA, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000;95:3052-3056
21. Cephalon, Inc. Cephalon receives FDA approval for Treanda, a novel chemotherapy for chronic lymphocytic leukemia [news release]. March 20, 2008. Available from www.cephalon.com/media/news-releases/article/cephalon-receives- fda-approval-fortreanda- a-novel-chemotherapy-for-chronic-lymphocyticleukemia/. Accessed December 2, 2008.
22. National Cancer Institute. FDA approval for bendamustine hydrochloride. Available from http://www.cancer.gov/cancertopics/druginfo/fda-bendamustine- hydrochloride. Accessed March 29, 2009.
23. Ozegowski W, Krebs D. IMET 3393, gamma-(1-methyl-5-bis([beta]- chloräthyl)-amino-benzimidazoyl(2)-buttersäurehydrochlorid, ein neus Zytostatikum aus der Reihe der Benzimidazol-Loste. Zbl Pharm 1971;110:1013-1019
24. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-3389
25. Gandhi V. Metabolism and mechanism of action of bendamustine: rationales for combination therapies. Semin Oncol 2002;29(4):4-11. (Pubitemid 34857890)
26. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-210
27. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-1288 (Pubitemid 41375295)
28. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the east Germany study group of hematology and oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205-212 (Pubitemid 43144255)
29. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL study group. Haematologica 2005;90:1357-1364 (Pubitemid 41503651)
30. Von Minckwitz G, Chernozernsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anti-Cancer Drugs 2005;16:871-877 (Pubitemid 41215753)
31. Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, Keilholz U. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007;55:109-113 (Pubitemid 46043579)
32. Koster W, Heider A, Niederle N, et al. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thoracic Oncol 2007;2:312-316 (Pubitemid 47181714)
33. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-317
34. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anti-Cancer Drugs 1996;7:415-421 (Pubitemid 26249195)
35. Barman Balfour JA, Goa K. Bendamustine. Drugs 2001;61:631-638
36. Wooley DW. Some biological effects produced by benzimidazole and their reversal by purines. J Biol Chem 1944;152:225-232
37. Hirschberg E, Gellhorn A, Gump WS. Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chlorethyl0 aminomethyl] benzimidazole and of other 2-chlorethyl compounds. Cancer Res 1957;17:904-910
38. Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 1972;287:386-389
39. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer screen using a diverse panel of cultured human cell lines. J Natl Cancer Inst 1991;83:757-766
40. Developmental Therapeutics Program, National Cancer Institute, National Institutes of Health. Screening services: DTP human tumor cell line screen. Available from http://dtp. nci.nih.gov/branches/btb/ivclsp.html. Accessed March 29, 2009.
41. Cephalon Inc. Treanda (bendamustine hydrochloride) package insert. Frazer, PA; 2008.
42. Apostolopoulos C, Castellano L, Stebbing J, Giamas G. Bendamustine as a model for the activity of alkylating agents. Future Oncol 2008;4(3):323-332 (Pubitemid 351984083)
43. Matthias M, Preiss R, Sohr R, et al. Pharmacokinetics of bendamustine in patients with malignant tumors [abstract]. Proc Am Soc Clin Oncol 1995;14:458.
44. Preiss R, Sohr R, Matthias M, et al. Pharmacokinetics of bendamustine (Cytostasan) in patients. Pharmazie 1985;40:782-784
45. Haase D, Preiss R, Sohr R. Untersuchungen zur plasmaeiweiBbinding von bendamustine (Cytostasan) und ambazon. Z Klin Med 1990;45:1267-1272 (Pubitemid 20276741)
46. Teichert J, Reinhard S, Hennig L, et al. Identification and quantitation of the N-acetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride. Drug Metab Dispos 2009;37(2):292-301.
47. Flockhart DA. Cytochrome P450 drug-interaction table. Available from www.medicine.iupui.edu/flockhart/. Accessed December 2, 2008.
48. Horn JP, Hansten PD. Get to know an enzyme: CYP1A2. Pharmacy Times 2007:76.
49. Knauf WU, Lissichov T, Aldaoud A, et al. Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: an updated analysis from an international phase III study [abstract]. Blood 2008;112:abstract 2091.
50. Cheson BD, Bennett JM, Grever M, et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997 (Pubitemid 26189840)
51. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia. Blood 2001;98:2319-2325
52. Fischer K, Stilgenbauer S, Schweighofer C, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG) [abstract]. Blood 2008;112:abstract 330.
53. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non- Hodgkin's lymphoma and mantle cell lymphoma: results of a randomized phase III trial (OSHO 19). J Cancer Res Clin Oncol 2006;132:105-112
54. Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas: a multicenter phase II study of the German low grade lymphomas study group (GLSG). Leuk Lymphoma 2007;48:1299-1306 (Pubitemid 47082223)
55. Fenk R, Michael M, Zohren F, et al. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007;48:2345-2351 (Pubitemid 350253466)
56. Reichmann U, Bokemeyer C, Wallwiener D, Bamberg M, Huober J. Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. Ann Oncol 2007;18:1981-1984 (Pubitemid 350286235)
57. Hartmann JT, Mayer F, Schleicher J, et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase II study of the German sarcoma group (AIO-001). Cancer 2007;110:861-866 (Pubitemid 47257665)
58. Schmidt-Hieber M, Schmittel A, Thiel E, Keilholz U. A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma. Melanoma Res 2004;14(6):439-442 (Pubitemid 40221132)
59. National Institutes of Health. ClinicalTrials.gov. Available from www.clinicaltrials.gov. Accessed December 1, 2008.
60. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Antiemesis. Available from www.nccn.org. Accessed December 1, 2008.
61. Aviado M, Becker K, Neise M, Strupp C, Losem C, Haas R. Bendamustine is an efficient and well tolerated option in the palliation of pretreated B-cell chronic lymphatic leukemias (CLL) [abstract]. Proc Am Soc Clin Oncol 2001;20:abstract 1220.
62. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anti-Cancer Drugs 2001;12:725-729 (Pubitemid 33001185)
63. Kath R, Blumenstengel K, Fricke HJ, Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001;127:48-54. (Pubitemid 32128513)
64. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006;132:99-104. (Pubitemid 41752051)